Evidence map›Paper›PMID 29026299›Full record

ArticleInternational journal of nanomedicine2017

Glycogen-gold nanohybrid escalates the potency of silymarin.

Raghuram Kandimalla, Suvakanta Dash, Ashim Chandra Bhowal, Sanjeeb Kalita, Narayan Chandra Talukdar, Sarathi Kundu, Jibon Kotoky

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Raghuram KandimallaDrug Discovery Lab, Institute of Advanced Study in Science and Technology.
Suvakanta DashGirijananda Choudhury Institute of Pharmaceutical Sciences.
Ashim Chandra BhowalSoft Nano Laboratory, Institute of Advanced Study in Science and Technology.
Sanjeeb KalitaDrug Discovery Lab, Institute of Advanced Study in Science and Technology.
Narayan Chandra TalukdarDrug Discovery Lab, Institute of Advanced Study in Science and Technology.
Sarathi KunduSoft Nano Laboratory, Institute of Advanced Study in Science and Technology.
Jibon KotokyDrug Discovery Lab, Institute of Advanced Study in Science and Technology.
Drug Discovery Laboratory (Norway) · NOInstitute of Advanced Study in Science and Technology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, a glycogen-gold nanohybrid was fabricated to enhance the potency of a promising hepatoprotective agent silymarin (Sly) by improving its solubility and gut permeation. By utilizing a facile green chemistry approach, biogenic gold nanoparticles were synthesized from

Indexed as

AnimalsAntioxidantsBiomarkersCarbon TetrachlorideCell SurvivalCytokinesGlycogenGoldHumansInflammation MediatorsLipid PeroxidationLiverMaleMetal NanoparticlesMicePlant ExtractsAntioxidantsBiomarkersCarbon TetrachlorideCytokinesGlycogenGoldInflammation MediatorsPlant ExtractsProtective AgentsSilymarinSuperoxide DismutaseTumor Necrosis Factor-alphaAnnona reticulataglycogen–goldhepatoprotectionnanohybridpotencysilymarin

Identifiers

PMID29026299
PMCPMC5626415
OpenAlexW2759572648

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.